CN118900698A - 用于多发性骨髓瘤的靶向bcma的car-t细胞疗法 - Google Patents

用于多发性骨髓瘤的靶向bcma的car-t细胞疗法 Download PDF

Info

Publication number
CN118900698A
CN118900698A CN202380022977.0A CN202380022977A CN118900698A CN 118900698 A CN118900698 A CN 118900698A CN 202380022977 A CN202380022977 A CN 202380022977A CN 118900698 A CN118900698 A CN 118900698A
Authority
CN
China
Prior art keywords
cells
car
subject
optionally
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380022977.0A
Other languages
English (en)
Chinese (zh)
Inventor
范晓虎
乔丹·谢克特
莉达·帕考德
迈克尔·希尔施曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Legendary Biotechnology Usa
Nanjing Legend Biotechnology Co Ltd
Janssen Biotech Inc
Original Assignee
Legendary Biotechnology Usa
Nanjing Legend Biotechnology Co Ltd
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legendary Biotechnology Usa, Nanjing Legend Biotechnology Co Ltd, Janssen Biotech Inc filed Critical Legendary Biotechnology Usa
Publication of CN118900698A publication Critical patent/CN118900698A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202380022977.0A 2022-02-28 2023-02-27 用于多发性骨髓瘤的靶向bcma的car-t细胞疗法 Pending CN118900698A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263314968P 2022-02-28 2022-02-28
US63/314,968 2022-02-28
PCT/US2023/063352 WO2023164695A2 (en) 2022-02-28 2023-02-27 Bcma-targeted car-t cell therapy for multiple myeloma

Publications (1)

Publication Number Publication Date
CN118900698A true CN118900698A (zh) 2024-11-05

Family

ID=87762032

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380022977.0A Pending CN118900698A (zh) 2022-02-28 2023-02-27 用于多发性骨髓瘤的靶向bcma的car-t细胞疗法

Country Status (9)

Country Link
US (1) US20230270786A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486372A2 (cg-RX-API-DMAC7.html)
JP (1) JP2025507678A (cg-RX-API-DMAC7.html)
KR (1) KR20240158888A (cg-RX-API-DMAC7.html)
CN (1) CN118900698A (cg-RX-API-DMAC7.html)
AU (1) AU2023223523A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252674A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024010527A (cg-RX-API-DMAC7.html)
WO (1) WO2023164695A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12522645B2 (en) 2019-11-05 2026-01-13 Janssen Biotech, Inc. BCMA-targeted CAR-T cell therapy of multiple myeloma
GR1010884B (el) * 2023-08-30 2025-02-19 Janssen Biotech, Inc., Θεραπεια τ κυτταρων με χιμαιρικο υποδοχεα αντιγονου (car) με στοχευμενο αντιγονο ωριμανσης των β κυτταρων (bcma) για πολλαπλο μυελωμα
AU2025218081A1 (en) * 2024-02-05 2026-07-16 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025193685A1 (en) * 2024-03-12 2025-09-18 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania

Also Published As

Publication number Publication date
MX2024010527A (es) 2024-12-06
CA3252674A1 (en) 2023-08-31
AU2023223523A1 (en) 2024-09-26
JP2025507678A (ja) 2025-03-21
US20230270786A1 (en) 2023-08-31
WO2023164695A3 (en) 2023-10-05
EP4486372A2 (en) 2025-01-08
KR20240158888A (ko) 2024-11-05
WO2023164695A2 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
US20230270786A1 (en) Bcma-targeted car-t cell therapy for multiple myeloma
US20240000836A1 (en) Bcma-targeted car-t cell therapy for multiple myeloma
KR20240117530A (ko) 다발성 골수종을 위한 bcma를 표적으로 하는 car-t 세포 요법
DK202530747A1 (en) Bcma-targeted car-t cell therapy for multiple myeloma
US20250339527A1 (en) Bcma-targeted car-t cell therapy for multiple myeloma
US20250269024A1 (en) Bcma-targeted car-t cell therapy for multiple myeloma
WO2025231408A2 (en) Methods for treating multiple myeloma with car-t cells and bispecific antibodies
GR20230100701A (el) Θεραπεια τ κυτταρων με χιμαιρικο υποδοχεα αντιγονου (car) με στοχευμενο αντιγονο ωριμανσης των β κυτταρων (bcma) για πολλαπλο μυελωμα
TR2025015426T2 (tr) Multi̇pl mi̇yeloma yöneli̇k bcma hedefli̇ car-t hücre terapi̇si̇

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination